Edition:
United Kingdom

Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

13.08USD
16 Jan 2019
Change (% chg)

-- (--)
Prev Close
$13.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
133,160
52-wk High
$25.74
52-wk Low
$10.24

Latest Key Developments (Source: Significant Developments)

Intra-Cellular Therapies Inc - Co Has Determined To Discontinue Study 201
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Intra-Cellular Therapies Inc ::INTRA-CELLULAR THERAPIES ANNOUNCES UPDATE ON ITI-007-201 CLINICAL TRIAL FOR TREATMENT OF AGITATION IN PATIENTS WITH PROBABLE ALZHEIMER'S DISEASE.INTRA-CELLULAR THERAPIES INC - DMC CONCLUDED THAT STUDY 201 IS NOT LIKELY TO MEET ITS PRIMARY ENDPOINT UPON COMPLETION.INTRA-CELLULAR THERAPIES INC - DMC RECOMMENDED STUDY SHOULD BE STOPPED FOR FUTILITY.INTRA-CELLULAR THERAPIES INC - COMPANY HAS DETERMINED TO DISCONTINUE STUDY 201.INTRA-CELLULAR THERAPIES INC - DOES NOT EXPECT THAT RESULTS WILL IMPACT ANY OF ITS OTHER ONGOING DEVELOPMENT PROGRAMS..  Full Article

Intra-Cellular Therapies Reports Q2 Results
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Intra-Cellular Therapies Inc ::INTRA-CELLULAR THERAPIES PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.68.Q2 EARNINGS PER SHARE VIEW $-0.76 -- THOMSON REUTERS I/B/E/S.INTRA-CELLULAR THERAPIES - EXPECTS CASH, CASH EQUIVALENTS, & INVESTMENT SECURITIES OF $403.8 MILLION AS OF JUNE 30 TO BE USED FOR LUMATEPERONE PROGRAM.  Full Article

Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Intra-cellular Therapies Inc ::Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia.Intra-Cellular Therapies Inc - ‍food and drug administration granted fast track designation for lumateperone for treatment of Schizophrenia​.  Full Article

Intra-Cellular Therapies Q3 loss per share $0.53
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Intra-cellular Therapies Inc :Intra-Cellular Therapies reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.53.Q3 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Cash, cash equivalents, investment securities totaled $328.1 million at September 30, 2017, versus $384.1 million at December 31, 2016​.Expect to complete patient enrollment in our bipolar studies in 2018​.  Full Article